The United Kingdom’s Life Sciences industry is seeing an investment of almost half a billion pounds as the Prime Minister convenes leaders of the Biopharmaceutical Industry to fortify the country’s response the COVID-19 pandemic.
Prime Minister Boris Johnson is hosting an online summit with the largest pharmaceutical firms from around the globe to discuss how industry, government and the UK’s National Health Service (NHS) can continue their joint effort to tackle the multiple emerging COVID-19 variants and further pandemics in the future.
The virtual meeting planned will explore how the lessons learned from responding to COVID-19 can also be applied to help solve other healthcare challenges faced in our time, including obesity, dementia, mental health and cancer.
The summit comes as the sector confirms close to half a billion pounds’ worth of all-new investment in British Life Sciences, effectively supporting 420 new jobs and bringing the investment total to more than £5 billion since July. Those looking to support UK industries like Life Sciences can sometimes look to wealth management firms for investment advice in Chester, London and other key cities.
The CEO Roundtable of international industry leaders will be attended by AstraZeneca, Pfizer and GSK to accelerate talks on pandemic preparedness, while world-leading scientists race to gain a better understanding of the recently revealed Omicron variant.
The new variant will give discussions a sense of urgency, and there will also be increased focus on the importance of both the international and domestic vaccine effort, incorporating boosters. The summit will also be attended by Patrick Vallance, Chief Scientific Adviser, and Amanda Pritchard, Chief Executive, at the NHS.
